Epigenetic Dysregulation and Cancer Progression: How Epigenetic Modifications Shape Tumor Fate
DOI:
https://doi.org/10.64048/hir.v1n2.007Keywords:
Epigenetics, DNA methylation, Histone modifications, Tumor fate, Precision oncologyAbstract
Epigenetic modifications, including DNA methylation, histone modification, and non-coding RNAs, play crucial roles in regulating gene expression without altering the underlying DNA sequence. In cancer, these epigenetic processes are often disrupted, contributing to tumor initiation, growth, metastasis, and drug resistance. This article reviews the latest findings on epigenetic dysregulation in cancer, emphasizing how these modifications influence tumor behavior and presenting novel therapeutic strategies aimed at targeting the epigenome. Additionally, we explore the potential for integrating epigenetic biomarkers into precision oncology to enhance patient outcomes, with a focus on recent advancements from 2022 to 2025.
Downloads
References
CASTRO-MUÑOZ, L. J., ULLOA, E. V., SAHLGREN, C., LIZANO, M., DE LA CRUZ-HERNÁNDEZ, E. & CONTRERAS-PAREDES, A. 2023. Modulating epigenetic modifications for cancer therapy (Review). Oncol Rep, 49. https://doi.org/10.3892/or.2023.8496
CHEN, H., LIU, Y. & WEI, Z. 2025. MicroRNA editing shapes metastatic potential: Mechanistic insights. Molecular Cancer Research, 23, 445-460.
GUO, X., LI, M. & DENG, P. 2023. DNA methylation patterns shape immune microenvironment in cancer. Nature Communications, 14, 1103.
JOHNSON, L. R., TANAKA, H. & YOON, J. 2024. Circulating methylated ctDNA as a predictor of immunotherapy response. Cancer Discovery, 14, 250-265.
KIM, D. S., NGUYEN, T. & COSTA, A. 2025. H3K27ac remodeling promotes endocrine resistance in breast cancer. Journal of Clinical Oncology, 43, 112-123.
PATEL, R., KUMARI, S. & GOMEZ, R. 2025. Epigenetic signatures guide precision oncology: Clinical applications. Nature Reviews Cancer, 25, 55-72.
POTE, M. S., SINGH, D., M, A. A., SUCHITA, J. & GACCHE, R. N. 2024. Cancer metastases: Tailoring the targets. Heliyon, 10, e35369. https://doi.org/10.1016/j.heliyon.2024.e35369
SADIDA, H. Q., ABDULLA, A., MARZOOQI, S. A., HASHEM, S., MACHA, M. A., AKIL, A. S. A. & BHAT, A. A. 2024. Epigenetic modifications: Key players in cancer heterogeneity and drug resistance. Transl Oncol, 39, 101821. https://doi.org/10.1016/j.tranon.2023.101821
SMITH, T. J., KUMAR, N. & ALI, R. 2023. Targeting BET proteins with degraders: Preclinical and clinical advances. Trends in Cancer, 9, 210-222.
WANG, D., ZHANG, Y., LI, Q., LI, Y., LI, W., ZHANG, A., XU, J., MENG, J., TANG, L. & LYU, S. 2024. Epigenetics: Mechanisms, potential roles, and therapeutic strategies in cancer progression. Genes Dis, 11, 101020. https://doi.org/10.1016/j.gendis.2023.04.040
WANG, J., ZHOU, X. & SINGH, M. 2025. LncRNA modulation of immune checkpoints in solid tumors. Frontiers in Oncology, 15, 320-340.
ZHANG, L., XU, Y. & CHEN, K. 2024. LncRNA-PRC2 interactions promote melanoma metastasis through epigenetic remodeling. Nature Cancer, 5, 123-136.
Downloads
Published
Data Availability Statement
All proof and evidence provided to improve this commentary paper are available online and can be accessed from the appropriate reference in the reference list.
Issue
Section
License
Copyright (c) 2025 Farzand Farhad Hamid
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in Health Innovation Reports are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This means anyone is free to share and adapt the work, provided proper attribution is given to the original authors and source.
How to Cite
Health Innovation Reports (ISSN: 3080-7557) is licensed under a